Adverse Events Following Immunisation. Kevin Connolly Limerick, Sept. 22, 2016

Similar documents
Adverse Events Following. Kevin Connolly Waterford, Aug. 25, 2016

Adverse Events Following Immunisation. Kevin Connolly Castlebar June 27, 2018

Adverse Events Following Immunisation

Adverse events following Immunisation Common and Uncommon. Dr Anna Clarke National Immunisation Office September

Adverse Events Following Immunisation. Castlebar, Nov. 8, 2013 Kevin Connolly

Training for Inactivated Poliovirus Vaccine (IPV) introduction. Module 6. Inactivated poliovirus vaccine AEFI monitoring

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

Vaccination Lets work together. Presentation Outline. How vaccines work 22/08/2018. Dr Fiona Ryan IPC Course September 2018.

The National Immunisation Schedule. Dr Brenda Corcoran.

Monitoring Vaccines Introduction. Pia Caduff-Janosa MD May 2013

Vaccine safety messages

The National Immunisation Schedule. Dr Brenda Corcoran.

Safety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist

Thursday, 21 September Vaccine Safety HPV. Helen Petousis-Harris, PhD National Immunisation Workshop Sept 2017

Post Licensure Communication on Vaccine Safety among Regulator, Industry and Stakeholder

MEASLES, MUMPS, RUBELLA (MMR)

The HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland

Vaccine Hesitancy- Current Issues and Controversies including HPV vaccine. Dr Brenda Corcoran National Immunisation Office

Measles and Measles Vaccine

Don t let your child catch it

Human Papillomavirus Immunisation Programme. Background

Immunisation for pre-school children. three years and four months old

How do we know vaccines are safe?

Rotavirus. Factsheet for parents. Immunisation for babies up to a year old

HPV, Cancer and the Vaccination Programme

Lessons Learned from Adverse Events and Assessment of Causal Relationships. Neal A. Halsey Johns Hopkins University

Changes to the National Immunisation Programme. Dr Brenda Corcoran National Immunisation Office.

Global Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

Vaccines Work Version

Childhood immunisation: An Update

Don t let your child catch it

Vaccine administration. Dr Brenda Corcoran National Immunisation Office

Postmarketing surveillance of pandemic H1N1 vaccines

Current National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office.

vaccines. Lecture 16 Dr. Gary Mumaugh

Gardasil Network Development Project GARDASIL VACCINE QUESTIONNAIRE

National Pandemic Vaccination Programme

Priorix TM Measles, mumps and rubella vaccine (live, attenuated)

Joint Statement 2018 for the Victims of HPV Vaccines

Vaccinations for Adults

Immunise against HPV

US Efforts in Vaccine Safety. Roger Baxter, MD California Immunization Coalition Summit 2011

Vaccine Hesitancy. Kevin Connolly. Sept. 22 nd, 2016 Limerick

PHARMACOVIGILANCE GLOSSARY

Yukon School Immunization Program Grade 6 INFORMATION FOR PARENTS/GUARDIANS

Responding to Vaccine Safety Events

Facts about HPV vaccine

Vaccines. Dr. Gary Mumaugh

Vaccinology 2017 Hanoi, Vietnam October 2017

Varicella (Chickenpox) and Varicella Vaccines

MEASLES, MUMPS, RUBELLA (MMR)

The schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008

Routine Office Visits

Beating cervical cancer

Assessing Vaccine Safety Post Licensure. Neal A. Halsey Johns Hopkins University

Vaccine Confidence Current Issues and Controversies including HPV vaccine. Dr Brenda Corcoran National Immunisation Office

Preventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S.

Preventing human papillomavirus (HPV) cancers and diseases by vaccination

Immunisation in the Bay of Plenty and Lakes

National Immunisation News

Revised AEFI Guidelines: Executive Summary

Update on safety of pandemic influenza A (H1N1) vaccines

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

Measles, Mumps, Rubella (MMR) Vaccine discussion pack. an information guide for health professionals and parents

Measles, Mumps, Rubella (MMR) Vaccine discussion pack. an information guide for health professionals and parents

Measles Elimination Dr. Suzanne Cotter 4 th National Immunisation Conference 2007

Let s talk about protection Childhood Vaccination. Flipbook to support conversations with parents and caregivers

A Parent s Guide to Childhood Immunization. Be informed.

MODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE

Immunization Safety Surveillance

Midland infectious disease activity summary (MIDAS), Vol 6 (1), Dec 2016

The Cold Chain and Vaccine storage

Recommended vaccines in the United States. Maki Kano, MD September 23, 2017 Apple Time

The Ministry of Health recommends measles vaccines for all child care providers, children and parents to ensure they are protected against measles.

HPV doesn t concern men?

Saving Vaccines in the Americas: A Framework for Vaccine Safety Training

Cervical Cancer Prevention in Japan: Troubling Times

TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide)

HPV vaccine the global perspective

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

UNSCHEDULED VACCINATION OF CHILDREN AND YOUNG PEOPLE WHO HAVE OUTSTANDING ROUTINE IMMUNISATIONS. Service Specification

The Cold Chain and Vaccine storage

Questions and answers about HPV. Facts about the virus and the vaccine

PACKAGE LEAFLET: INFORMATION FOR THE USER

Vaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013

Health Care Workers (HCWs) in Ireland should have 2 doses of MMR vaccine. Two of the cases in recent outbreaks in Ireland were HCWs.

An introduction to Vaccine Post-marketing Safety Surveillance

Are you protected against measles mumps and rubella?

9/11/2018. HPV Yoga. Human Papillomavirus. Human Papillomavirus (HPV) Disease. Most common sexually transmitted infection in the U.S.

If you are not sure if your child is up to date with their MMR, please check with your GP.

NHS GRAMPIAN IMMUNISATION PROGRAMMES ANNUAL REPORT 2010/11

Vaccination schedules in Denmark

The National Immunisation Schedule Update and Current issues November Dr Brenda Corcoran National Immunisation Office.

Protection against tetanus, diphtheria and polio

The Cold Chain and Vaccine storage

Immunisation. for babies just after their first birthday

HPV Vaccine (Human Papillomavirus Vaccine)

Transcription:

Adverse Events Following Immunisation Kevin Connolly Limerick, Sept. 22, 2016

Outline Abbreviations, Definitions Adverse Event (AE), Adverse Reaction (AR) or coincidence? How are AEs recorded? How are ARs are identified? Frequency of ARs

Abbreviations AE- adverse event AR-adverse reaction AEFI-adverse event following immunisation SAE- serious adverse event

Definitions Adverse Event Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment Adverse Drug Reaction A response to a drug which is noxious and unintended,

Definitions Adverse Event Following Immunization (AEFI) Any untoward medical occurrence which follows immunisation and which does not necessarily have a causal relationship with the usage of the vaccine. The adverse event may be any unfavourable or unintended sign, abnormal laboratory finding, symptom or disease

Immunisation Error-related Reaction An adverse event following immunisation that is caused by inappropriate vaccine handling, prescribing or administration and thus by its nature is preventable.

Frequency of Reactions Very common.. >10% Common..1-10% Uncommon.1/100-1/1,000 Rare..1/1,000-1/10,000 Very rare <1/10,000

Known AEFIs Redness More Common (>1 in 100) Swelling, nodule Pain Fever, irritability, loss of appetite nausea, D+V Less Common (<1/100) Encephalitis Paralysis Arthritis Allergic reaction Thrombocytopoenia Febrile seizure Fainting Narcolepsy Death

What is Less Common? Frequency of known injury* 1/1,000 to 1/100,000 Fainting or collapse Febrile seizure Thrombocytopoenia 1/100,000 to 1/1,000,000 Serious allergic reaction Arthritis > 1 in a million Encephalitis Paralysis Death *highest rate for any childhood vaccine What else is this common? Having quadruplets Getting struck by lightning Winning the lottery

Presenting Risk Information 1. A serious reaction occurs about 1 to 3 times per 10,000 doses 2. About 1 to 3 children out of 10,000 will experience a serious reaction 3. This vaccine rarely causes serious reactions -about 1 to 3 children out of 10,000 who receive it 4. This vaccine is very safe -9,997 children out of 10,000 will experience no significant adverse reaction

Health problems caused by the vaccine AEFI -Coincidence or Vaccine Injury? All health problems after vaccination

What Causes AEFIs? Vaccine due to vaccine s inherent properties Programme, administration Injection reaction- anxiety, pain Unknown- cause cannot be determined

AEFIs: potential sources Manufacturing potency issues - over-attenuation of live vaccines - instability over time - reconstitution, mixing interferences Storage issues Administration issues - technique - concomitant administrations Patient profile - age, weight - immune deficiency e.g. AIDS Environmental - epidemiology: strain variation

AEFIs: potential sources Manufacturing potency issues - over-attenuation of live vaccines - instability over time - reconstitution, mixing interferences Storage issues Administration issues - technique - concomitant administrations Patient profile - age, weight - immune deficiency e.g. AIDS Environmental - epidemiology: strain variation

AEFIs: potential sources Manufacturing potency issues - over-attenuation of live vaccines - instability over time - reconstitution, mixing interferences Storage issues Administration issues - technique - concomitant administrations Patient profile - age, weight - immune deficiency e.g. AIDS Environmental - epidemiology: strain variation

Is this an AE or an AR?

AEFIs: potential sources Manufacturing potency issues - over-attenuation of live vaccines - instability over time - reconstitution, mixing interferences Storage issues Administration issues - technique - concomitant administrations Patient profile age, weight immune deficiency e.g. AIDS Environmental - epidemiology: strain variation

AEFIs: potential sources Manufacturing potency issues - over-attenuation of live vaccines instability over time reconstitution, mixing interferences Storage issues Administration issues technique concomitant administrations Patient profile age, weight immune deficiency e.g. AIDS Environmental strain variation

Timing of Vaccine Reactions Inactivated vaccines: generally within 48hrs Live vaccines: according to time for organism to replicate MMR: - mini-measles 6-11 days (SSPE years) -rubella 2 nd week -mumps 3to 6 weeks BCG: days -12 months +

Minimising Errors Right patient Right vaccine and diluent Right time (age, interval, expiry) Right dose Right site Right route Right documentation

Vaccine Safety Studies PHASE I Safety, tolerability May not involve target population 10-100 subjects PHASE II Safety, immunogenicity, dosing in target population 100 to 200 subjects PHASE III Safety, immunogenicity, duration of immune response, concomitant use, efficacy 1000s to 10,000s PHASE IV Safety and effectiveness; occurs after licensure N > 100,000.

Why Monitor AEFIs? No vaccine is 100% safe Safety profile established in pre-license trials Rare events require huge numbers to detect Risk / benefit balance changes over time as incidence falls-e.g. VAPP with oral polio vaccine as society becomes more critical

Pharmacovigilance Science and activities relating to the detection, assessment, understanding and prevention of adverse effects Objectives : preventing harm from adverse reactions promoting safe and effective use of medicinal products

Number needed to test for increased risk of an AE Rate In Vaccinated Population Backgroundrate in general population 2-fold higher 10-fold higher 100-fold higher 1 in 10,000 141,000 5,500 500 1 in 100,000 1,238,000 53,500 2,500 1 in 1,000,000 12,951,500 532,500 23,500 Evans D et al. J Infect Dis. 2009;200:321-8.

Benefit-risk balance Medicines may have unintended, harmful effects. Active substance tested in trials Licenced only if benefits outweigh risks Used in patients who may differ from the study population, e.g. age or additional diseases Important to identify any new risk ASAP, and to take measures to minimise risk and promote safe and effective us

Pharmacovigilance by Pharmaceutical Companies Legal obligations to continuously collect data and conduct pharmacovigilance Data must be sent to authorities within defined timelines Any emerging concern about the benefit-risk balance has to be notified immediately. Authorities may request further investigations, including formal studies. Authorities may update product information and implement other safety measures

Is Sequence Consequence? A Exposure (Vaccine, Drug, Diet, Occupation etc) Time B Disease Direct and only cause? One of multiple potential causes? Co-factor/indirect cause, trigger? Coincidental?

Spurious Correlations, tylerviggen.com Correlation is not Causation

Criteria of Causality (Bradford Hill) The Bad Dog Ate the Cat Temporality - occurs after, change in incidence over time Biological Plausibility -biological mechanism can make causality more plausible Dose -Response Relationship Association (strength of) - measured using RRs and ORs Consistency -similar results from different studies, researchers, populations, times

Adverse Reaction to Lectures

Reporting AEFIs <10% are reported Up to 99% are not reported Safety is provisional at time of licencing -Rotashield, Vioxx, Pandemrix, HRT Every report is important If in doubt, write one out

R.E.G.R.E.T. Reactions and effects of Gardasil resulting in extreme trauma

R.E.G.R.E.T. set up by parents of Irish teenage girls who have developed serious health problems after entering secondary school. These parents are certain that the HPV vaccine (Gardasil) is the cause of their daughters' otherwise unexplained illness. One is entitled to one s beliefs and feelings, but not to one s own science

Problems with REGRET S Beliefs Sampling, recall, susceptibility bias Incidence of CFS in population, in trials, after introduction of HPV vaccines EMA, WHO assessment The overwhelming body of scientific evidence is that there i no causative association between HPV vaccines and POTS, CFS or CRPS

Remember.. Incidence of HPV-related cancers Effectiveness of HPV vaccine

Estimated Impact of HPV Vaccination In the 9 years since HPV vaccine introduced: HPV Genital infection reduced by 64-85%¹ CIN2 + 3 reduced by 75%² ¹ US, Australia ² 3m. girls, Sweden, 2006-13, vaccinated <17yrs. International Journal of Cancer (2016).

Estimated Impact of nohpv Vaccination Currently 500,000 girls <15 in Ireland; if none are vaccinated: 3,500 will develop cervical cancer 1,000 will die from cervical cancer 80% uptake would prevent 1600 cases of cancer and 500 deaths

The End

Unsure if applause is because I was good? or because I have shut-up